{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T02:10:16Z","timestamp":1743905416969,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","award":["2017 Career Development Award"],"award-info":[{"award-number":["2017 Career Development Award"]}],"id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["3U01AA021840-07S1"],"award-info":[{"award-number":["3U01AA021840-07S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10620-020-06632-5","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T08:03:16Z","timestamp":1603094596000},"page":"3062-3073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes in Serum Myostatin Levels in Alcoholic Hepatitis Correlate with Improvement in MELD"],"prefix":"10.1007","volume":"66","author":[{"given":"Hani","family":"Shamseddeen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Madathanapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay S.","family":"Are","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiebing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla","family":"Gelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa A.","family":"Zimmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-2370","authenticated-orcid":false,"given":"Archita P.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"6632_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/cld.806","volume":"13","author":"JL Mellinger","year":"2019","unstructured":"Mellinger JL. Epidemiology of alcohol use and alcoholic liver disease. Clin Liver Dis. 2019;13:136\u2013139.","journal-title":"Clin Liver Dis"},{"key":"6632_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.14309\/ajg.0000000000000380","volume":"115","author":"K Dang","year":"2020","unstructured":"Dang K, Hirode G, Singal AK, Sundaram V, Wong RJ. Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases. Am J Gastroenterol. 2020;115:96\u2013104.","journal-title":"Am J Gastroenterol"},{"key":"6632_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/acer.14239","volume":"44","author":"AM White","year":"2020","unstructured":"White AM, Castle I-JP, Hingson RW, Powell PA. Using death certificates to explore changes in alcohol-related mortality in the United States, 1999 to 2017. Alcohol Clin Exp Res. 2020;44:178\u2013187.","journal-title":"Alcohol Clin Exp Res"},{"doi-asserted-by":"crossref","unstructured":"Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice\nguidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71:306\u2013333.","key":"6632_CR4","DOI":"10.1002\/hep.30866"},{"key":"6632_CR5","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1056\/NEJMra0805786","volume":"360","author":"MR Lucey","year":"2009","unstructured":"Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758\u20132769.","journal-title":"N Engl J Med"},{"key":"6632_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cld.2016.02.007","volume":"20","author":"PM Gholam","year":"2016","unstructured":"Gholam PM. Prognosis and prognostic scoring models for alcoholic liver disease and acute alcoholic hepatitis. Clin Liver Dis. 2016;20:491\u2013497.","journal-title":"Clin Liver Dis"},{"key":"6632_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/apt.15376","volume":"50","author":"K Bennett","year":"2019","unstructured":"Bennett K, Enki DG, Thursz M, Cramp ME, Dhanda AD. Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis. Aliment Pharmacol Ther. 2019;50:249\u2013257.","journal-title":"Aliment Pharmacol Ther"},{"key":"6632_CR8","doi-asserted-by":"publisher","first-page":"e0192393","DOI":"10.1371\/journal.pone.0192393","volume":"13","author":"E Hughes","year":"2018","unstructured":"Hughes E, Hopkins LJ, Parker R. Survival from alcoholic hepatitis has not improved over time. PloS One. 2018;13:e0192393.","journal-title":"PloS One"},{"key":"6632_CR9","doi-asserted-by":"publisher","first-page":"6279","DOI":"10.3748\/wjg.v20.i20.6279","volume":"20","author":"M Chayanupatkul","year":"2014","unstructured":"Chayanupatkul M. Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment. World J Gastroenterol. 2014;20:6279.","journal-title":"World J Gastroenterol"},{"key":"6632_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jhep.2018.10.041","volume":"70","author":"M Thursz","year":"2019","unstructured":"Thursz M, Kamath PS, Mathurin P, Szabo G, Shah VH. Alcohol-related liver disease: areas of consensus, unmet needs and opportunities for further study. J Hepatol. 2019;70:521\u2013530.","journal-title":"J Hepatol"},{"key":"6632_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83\u201390.","journal-title":"Nature"},{"key":"6632_CR12","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1126\/science.1069525","volume":"296","author":"TA Zimmers","year":"2002","unstructured":"Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science. 2002;296:1486\u20131488.","journal-title":"Science"},{"key":"6632_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/jcsm.12302","volume":"9","author":"L-N Peng","year":"2018","unstructured":"Peng L-N, Lee W-J, Liu L-K, Lin M-H, Chen L-K. Healthy community-living older men differ from women in associations between myostatin levels and skeletal muscle mass: myostatin levels and skeletal muscle mass. J Cachexia Sarcopenia Muscle. 2018;9:635\u2013642.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6632_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12877-018-0888-y","volume":"18","author":"E Fife","year":"2018","unstructured":"Fife E, Kostka J, Kroc \u0141, et al. Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men. BMC Geriatr. 2018;18:200.","journal-title":"BMC Geriatr"},{"key":"6632_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijcard.2016.06.231","volume":"220","author":"T Furihata","year":"2016","unstructured":"Furihata T, Kinugawa S, Fukushima A, et al. Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure. Int J Cardiol. 2016;220:483\u2013487.","journal-title":"Int J Cardiol"},{"key":"6632_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.rmed.2011.07.016","volume":"106","author":"C-R Ju","year":"2012","unstructured":"Ju C-R, Chen R-C. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease. Respir Med. 2012;106:102\u2013108.","journal-title":"Respir Med"},{"key":"6632_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16\u201331.","journal-title":"Age Ageing"},{"key":"6632_CR18","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1097\/TP.0000000000003222","volume":"104","author":"E Mauro","year":"2020","unstructured":"Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list. Transplantation. 2020;104:e188\u2013e198.","journal-title":"Transplantation"},{"doi-asserted-by":"publisher","unstructured":"Vural A, Attaway A, Welch N, Zein J, Dasarathy S. Skeletal muscle loss phenotype in cirrhosis: a nationwide analysis of hospitalized patients. Clin Nutr. 2020. https:\/\/doi.org\/10.1016\/j.clnu.2020.03.032.","key":"6632_CR19","DOI":"10.1016\/j.clnu.2020.03.032"},{"key":"6632_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1213\/ANE.0b013e3181eac1c9","volume":"111","author":"PS Garc\u00eda","year":"2010","unstructured":"Garc\u00eda PS, Cabbabe A, Kambadur R, Nicholas G, Csete M. Elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. Anesth Analg. 2010;111:707\u2013709.","journal-title":"Anesth Analg"},{"key":"6632_CR21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/jcsm.12212","volume":"8","author":"H Nishikawa","year":"2017","unstructured":"Nishikawa H, Enomoto H, Ishii A, et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis: myostatin and liver cirrhosis. J Cachexia Sarcopenia Muscle. 2017;8:915\u2013925.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6632_CR22","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2019.3.03","author":"L Skladany","year":"2019","unstructured":"Skladany L, Koller T, Molcan P, et al. Prognostic usefulness of serum myostatin in advanced chronic liver disease: its relation to gender and correlation with inflammatory status. J Physiol Pharmacol Off J Pol Physiol Soc. 2019;. https:\/\/doi.org\/10.26402\/jpp.2019.3.03.","journal-title":"J Physiol Pharmacol Off J Pol Physiol Soc"},{"key":"6632_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00535-019-01605-6","volume":"54","author":"M Ebadi","year":"2019","unstructured":"Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol. 2019;54:845\u2013859.","journal-title":"J Gastroenterol"},{"key":"6632_CR24","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/liv.14358","volume":"40","author":"N Welch","year":"2020","unstructured":"Welch N, Dasarathy J, Runkana A, et al. Continued muscle loss increases mortality in cirrhosis: impact of aetiology of liver disease. Liver Int. 2020;40:1178\u20131188.","journal-title":"Liver Int"},{"key":"6632_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/MEG.0000000000001583","volume":"32","author":"Y Al-Azzawi","year":"2020","unstructured":"Al-Azzawi Y, Albo B, Fasullo M, et al. Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis. Eur J Gastroenterol Hepatol. 2020;32:733\u2013738.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"6632_CR26","doi-asserted-by":"publisher","first-page":"E916","DOI":"10.1152\/ajpendo.00554.2003","volume":"286","author":"CH Lang","year":"2004","unstructured":"Lang CH, Frost RA, Svanberg E, Vary TC. IGF-I\/IGFBP-3 ameliorates alterations in protein synthesis, eIF4E availability, and myostatin in alcohol-fed rats. Am J Physiol Endocrinol Metab. 2004;286:E916\u2013E926.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"6632_CR27","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.cgh.2016.05.041","volume":"14","author":"S Liangpunsakul","year":"2016","unstructured":"Liangpunsakul S, Puri P, Shah VH, et al. Effects of age, sex, body weight, and quantity of alcohol consumption on occurrence and severity of alcoholic hepatitis. Clin Gastroenterol Hepatol. 2016;14:1831\u20131838.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6632_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/hep4.1123","volume":"2","author":"S Liangpunsakul","year":"2018","unstructured":"Liangpunsakul S, Beaudoin JJ, Shah VH, et al. Interaction between the patatin-like phospholipase domain-containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. Hepatol Commun. 2018;2:29\u201334.","journal-title":"Hepatol Commun"},{"unstructured":"RStudio Team. RStudio: integrated development environment for R. Boston, MA: RStudio, Inc.; 2018.","key":"6632_CR29"},{"key":"6632_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H. ggplot2: Elegant graphics for data analysis. Berlin: Springer; 2016."},{"key":"6632_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.coph.2009.04.008","volume":"9","author":"S Sanjabi","year":"2009","unstructured":"Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol. 2009;9:447\u2013453.","journal-title":"Curr Opin Pharmacol"},{"key":"6632_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/acer.14221","volume":"44","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang F, Modrak S, Little A, Zhang H. Chronic alcohol consumption enhances skeletal muscle wasting in mice bearing cachectic cancers: the role of TNF\u03b1\/myostatin axis. Alcohol Clin Exp Res. 2020;44:66\u201377.","journal-title":"Alcohol Clin Exp Res"},{"key":"6632_CR33","doi-asserted-by":"publisher","first-page":"e0141035","DOI":"10.1371\/journal.pone.0141035","volume":"10","author":"S Yano","year":"2015","unstructured":"Yano S, Nagai A, Isomura M, et al. Relationship between blood myostatin levels and kidney function: shimane cohre study. PloS One. 2015;10:e0141035.","journal-title":"PloS One"},{"key":"6632_CR34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","volume":"150","author":"DW Crabb","year":"2016","unstructured":"Crabb DW, Bataller R, Chalasani NP, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia. Gastroenterology. 2016;150:785\u2013790.","journal-title":"Gastroenterology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06632-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06632-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06632-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T07:52:05Z","timestamp":1634629925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06632-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["6632"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06632-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For full disclosure, Dr. Naga Chalasani has ongoing paid consulting activities (or had in preceding 12\u00a0months) with NuSirt, Abbvie, Afimmune (DS Biopharma), Allergan (Tobira), Madrigal, Siemens, Foresite, Galectin, Zydus, and La Jolla. These consulting activities are generally in the areas of nonalcoholic fatty liver disease and drug hepatotoxicity. Dr. Chalasani receives research grant support from Exact Sciences, Intercept, and Galectin Therapeutics where his institution receives the funding. Over the last decade, Dr. Chalasani has served as a paid consultant to more than 35 pharmaceutical companies and these outside activities have regularly been disclosed to his institutional authorities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}